Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study
Launched by UNIVERSITY OF PARMA · Jun 3, 2019
Trial Information
Current as of June 22, 2025
Unknown status
Keywords
ClinConnect Summary
The need for continuous anticoagulation represents a potential drawback of RRT modalities. KDIGO 2012 guidelines on acute kidney injury (AKI) suggest the adoption of RCA as first choice anticoagulation modality for continuous RRT (CRRT) in patients without contraindications for citrate. Citrate has been also introduced as anticoagulant for SLED and its use in the context of a mainly diffusive prolonged intermittent modality has been shown to represent an easy and safe method to maintain the extracorporeal circuit when concentrated citrate solutions, such as ACD-A are used. Hypophosphatemia ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age \>= 18 years
- • critically ill patients requiring continuous or prolonged intermittent renal replacement therapy for severe acute kidney injury (AKI)
- • critically ill patients requiring continuous or prolonged intermittent renal replacement therapy for end stage renal disease (ESRD)
- Exclusion Criteria:
- • age \< 18 years
About University Of Parma
The University of Parma is a prestigious academic institution in Italy, renowned for its commitment to research and innovation in the field of healthcare. As a clinical trial sponsor, it leverages its extensive expertise and resources to advance medical knowledge and improve patient outcomes through rigorous scientific investigation. The university fosters collaboration between multidisciplinary teams, encompassing researchers, healthcare professionals, and industry partners, to ensure the highest standards of clinical research. Its focus on ethical practices and adherence to regulatory guidelines underscores its dedication to contributing valuable insights to the medical community and enhancing public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Parma, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials